applicable margins; and (vi) modifications to certain covenants and events of default. Net proceeds from the Term Loan shall be used to fund ongoing working capital, capital expenditures, permitted distributions, permitted acquisitions and general corporate purposes of the Company and its subsidiaries.
The Company paid $993 in financing costs in connection with the Second Amendment, which will be amortized over the term of the loan. The Company wrote off $370 in deferred financing fees pertaining to the Previous Credit Agreement associated with a bank exiting the Second Amendment. The remaining balance of deferred financing costs pertaining to the remaining bank associated with the Previous Credit Agreement of $277 will be amortized over the term of the Second Amendment. The portion of the deferred financing costs associated with the Amended Line of Credit and the Term Loan are reflected in other assets and as a reduction of the Term Loan, respectively, in the condensed consolidated balance sheet at June 30, 2022.
The Second Amendment is collateralized by certain assets of the Company and contains financial and operating covenants. The Company was in compliance with these covenants at June 30, 2022.
Term Loan
The Term Loan requires quarterly principal payments over five years, with a balloon payment due on March 8, 2027. The interest rate on the Term Loan was 2.63% at June 30, 2022 as the Company selected the SOFR Option. Term Loan outstanding amounts are reported in the current portion of long-term debt and long-term debt, net of current portion, in the condensed consolidated balance sheets.
Amended Line of Credit
The Amended Line of Credit expires in March 2027. The Company is required to pay a quarterly fee on the difference between the $200,000 allowed maximum borrowings and the unpaid principal balance outstanding under the line at the applicable rate. At June 30, 2022, the New Base Rate Option and SOFR Option applicable to Amended Line of Credit borrowings were 4.75% and 2.63%, respectively. There were 0 outstanding borrowings under the Amended Line of Credit at June 30, 2022 or the Previous Line of Credit at December 31, 2021, respectively.
10.STOCKHOLDERS’ EQUITY
Common Stock
During the three and six months ended and June 30, 2022, the Company issued 93 and 365 shares of Class A common stock (“Class A”), respectively, related to the exercise of options, net of 23 and 70 shares, respectively, returned to the Company in lieu of payment of the exercise price and taxes due on these exercises.
During the three and six months ended June 30, 2022, the Company issued 0 and 3 shares of Class A common stock, respectively, in connection with the vesting of Restricted Stock Units (“RSUs”), net of 0 and 1 share, respectively, returned to the Company in lieu of payment of taxes due on the vesting of these RSUs.
During the three and six months ended June 30, 2022, the Company issued 59 shares of Class A common stock in connection with the vesting of Restricted Stock Awards (“RSAs”).
During the three and six months ended June 30, 2022, a stockholder exchanged 5,500 shares of Class B common stock for an equivalent number of shares of Class A common stock.
During the three and six months ended and June 30, 2021, the Company issued 462 and 1,102 shares of Class A common stock (“Class A”), respectively, related to the exercise of options, net of 219 and 575 shares, respectively, returned to the Company in lieu of payment of the exercise price and taxes due on these exercises.
During the three and six months ended June 30, 2021, the Company issued 0 and 5 shares of Class A, respectively, in connection with the vesting of RSUs, net of 0 and 1 shares, respectively, returned to the Company in lieu of payment of taxes due on the vesting of these RSUs.